RxDoctor Payments DataLook up a doctor →

Omar Wani, MD

Cardiovascular Disease · Flagstaff, AZNPI 1326265893

Payments from drug & device makers

$295,231in general payments, 2019–2025

Across 420 payments — averaging $702.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$150K
  • Amarin Pharma, Inc.$119K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
  • Boston Scientific$2K
  • Abiomed$508
  • Novartis$477
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$197,39581%
  • Travel & lodging$35,29314%
  • Food & beverage$11,4425%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$295,231 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$448,297
Medicare patients
2,288
Services billed
6,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl160$152,042
EliquisApixaban79$102,338
Repatha SyringeEvolocumab31$39,945
Repatha SureclickEvolocumab42$38,229
EntrestoSacubitril/Valsartan20$24,467
Icosapent Ethyl44$16,806
Ezetimibe196$6,641
Metoprolol Succinate216$2,971
Pravastatin Sodium137$1,824
Atorvastatin Calcium138$1,794
Rosuvastatin Calcium89$1,673
Ranolazine ErRanolazine16$1,423
Nebivolol Hcl15$1,086
Amlodipine Besylate61$525
Losartan Potassium59$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$102,33879 claims
NovartisEntresto$477$24,46720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Flagstaff

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →